Phase I results for bortezomib in children with refractory solid tumors
This article has no abstract so we have provided the first paragraph of the full text.
Bortezomib, a proteasome inhibitor, has shown activity against a variety of tumor types in preclinical studies and has been licensed as a third-line treatment for adults with multiple myeloma. Blaney et al. have recently reported the results of their phase I study of bortezomib in children with recurrent or refractory solid tumors.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.